Vertex Pharmaceuticals Förvaltning

Förvaltning kriterier kontrolleras 2/4

Vertex Pharmaceuticals VD är Reshma Kewalramani, utsedd i Apr 2020, har en mandatperiod på 5.08 år. totala årliga ersättningen är $ 21.54M, bestående av 7.2% lön 92.8% bonusar, inklusive företagsaktier och optioner. äger direkt 0.016% av företagets aktier, värda € 16.17M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 5.6 år respektive 5.3 år.

Viktig information

Reshma Kewalramani

Verkställande direktör

US$21.5m

Total ersättning

VD-lön i procent	7.16%
Anställning som VD	5.1yrs
Ägande av VD	0.02%
Ledningens genomsnittliga anställningstid	5.6yrs
Styrelsens genomsnittliga mandatperiod	5.3yrs

Senaste uppdateringar av ledningen

Recent updates

Analys av ersättningar till VD

Hur har Reshma Kewalramani:s ersättning förändrats jämfört med Vertex Pharmaceuticals:s resultat?
Datum	Total ersättning	Lön	Företagets resultat
Mar 31 2025	n/a	n/a	-US$989m
Dec 31 2024	US$22m	US$2m	-US$536m
Sep 30 2024	n/a	n/a	-US$480m
Jun 30 2024	n/a	n/a	-US$490m
Mar 31 2024	n/a	n/a	US$4b
Dec 31 2023	US$21m	US$2m	US$4b
Sep 30 2023	n/a	n/a	US$3b
Jun 30 2023	n/a	n/a	US$3b
Mar 31 2023	n/a	n/a	US$3b
Dec 31 2022	US$16m	US$1m	US$3b
Sep 30 2022	n/a	n/a	US$3b
Jun 30 2022	n/a	n/a	US$3b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	US$15m	US$1m	US$2b
Sep 30 2021	n/a	n/a	US$2b
Jun 30 2021	n/a	n/a	US$2b
Mar 31 2021	n/a	n/a	US$3b
Dec 31 2020	US$9m	US$1m	US$3b
Sep 30 2020	n/a	n/a	US$3b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$7m	US$702k	US$1b

Ersättning vs marknad: Reshma s total kompensation ($USD 21.54M ) är över genomsnittet för företag av liknande storlek på German marknaden ($USD 5.21M ).

Ersättning vs inkomst: Ersättningen för Reshma har ökat samtidigt som företaget är olönsamt.

VD OCH KONCERNCHEF

Reshma Kewalramani (51 yo)

5.1yrs

Anställning

US$21,538,668

Kompensation

Dr. Reshma Kewalramani, M.D., FASN, is Director at Year Up Inc. since September 2023. She had been an Independent Director of Ginkgo Bioworks Holdings, Inc. (formerly known as Ginkgo Bioworks, Inc.) since...

Ledningsgrupp

Namn	Position	Anställning	Kompensation	Ägarskap
Jeffrey Leiden	Executive Chairman	15.8yrs	US$6.57m	0.0095% € 9.5m
Reshma Kewalramani	CEO, President & Director	5.1yrs	US$21.54m	0.016% € 16.2m
Charles Wagner	Executive VP & CFO	6.1yrs	US$8.00m	0.011% € 11.3m
Stuart Arbuckle	Executive VP & COO	3.8yrs	US$9.38m	0.0092% € 9.2m
David Altshuler	Executive VP & Chief Scientific Officer	10.3yrs	US$7.64m	0.0013% € 1.3m
Ourania Tatsis	Executive VP and Chief Regulatory & Quality Officer	7.7yrs	US$7.33m	0.012% € 11.7m
Kristen Ambrose	Senior VP & Chief Accounting Officer	4yrs	inga uppgifter	0.0031% € 3.0m
Susie Lisa	Senior Vice President of Investor Relations	2.7yrs	inga uppgifter	inga uppgifter
Jonathan Biller	Executive VP & Chief Legal Officer	2.7yrs	inga uppgifter	0.0069% € 6.8m
Nina Devlin	Senior VP & Chief Communications Officer	6.3yrs	inga uppgifter	inga uppgifter
Stephanie Franklin	Senior VP & Chief Human Resources Officer	7.8yrs	inga uppgifter	inga uppgifter
Amit Sachdev	Executive VP & Chief Patient and External Affairs Officer	17.8yrs	US$6.20m	0.027% € 26.8m

5.6yrs

Genomsnittlig anställningstid

56yo

Genomsnittlig ålder

Erfaren ledning: VX1 s ledningsgrupp är erfaren och erfaren ( 5.6 års genomsnittlig anställning).

Styrelseledamöter

Namn	Position	Anställning	Kompensation	Ägarskap
Jeffrey Leiden	Executive Chairman	15.8yrs	US$6.57m	0.0095% € 9.5m
Reshma Kewalramani	CEO, President & Director	5.3yrs	US$21.54m	0.016% € 16.2m
Bruce Sachs	Lead Independent Director	27.3yrs	US$603.19k	0.016% € 15.5m
Alan Garber	Independent Director	7.9yrs	US$521.86k	0.0025% € 2.5m
Lloyd Carney	Independent Director	6.3yrs	US$564.18k	0.0025% € 2.4m
Sangeeta Bhatia	Independent Director	9.9yrs	US$550.11k	0.0016% € 1.6m
Michel Lagarde	Independent Director	1.6yrs	US$538.52k	0.00044% € 437.1k
Diana McKenzie	Independent Director	4.9yrs	US$549.96k	0.00064% € 635.7k
Suketu Upadhyay	Independent Director	3yrs	US$562.97k	0.00061% € 605.9k
Nancy Thornberry	Independent Director	1.4yrs	US$519.27k	0.00064% € 635.7k
Jennifer Schneider	Independent Director	1yr	US$495.87k	0% € 0

5.3yrs

Genomsnittlig anställningstid

59yo

Genomsnittlig ålder

Erfaren styrelse: VX1 s styrelse anses vara erfaren ( 5.3 års genomsnittlig mandatperiod).

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2025/05/14 08:07
Aktiekurs vid dagens slut	2025/05/14 00:00
Intäkter	2025/03/31
Årlig intjäning	2024/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om den analysmodell som används för att generera denna rapport finns på vår Github-sida, vi har också guider om hur man använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Vertex Pharmaceuticals Incorporated bevakas av 66 analytiker. 32 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Jasper Hellweg	Argus Research Company
Brian Skorney	Baird
Ishan Majumdar	Baptista Research

Vertex Pharmaceuticals Förvaltning

Förvaltning kriterier kontrolleras 2/4

Viktig information

Senaste uppdateringar av ledningen

Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 14, 2025

Vertex Pharmaceuticals Incorporated Executive Changes

Vertex Pharmaceuticals Incorporated Appoints Jennifer Schneider as Independent Director

Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 15, 2024

Vertex Pharmaceuticals Incorporated Appoints Nancy Thornberry to Its Board of Directors as an Independent Director

Vertex Pharmaceuticals Incorporated Appoints Michel Lagarde to Its Board of Directors

Recent updates

First quarter 2025 earnings released: EPS: US$2.52 (vs US$4.26 in 1Q 2024)

Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full-Year 2025

ToolGen Files Patent Infringement Lawsuit Against Vertex in the United Kingdom

Vertex Pharmaceuticals Incorporated to Report Q1, 2025 Results on May 05, 2025

Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 14, 2025

Vertex Pharmaceuticals Incorporated Announces Program Updates for Type 1 Diabetes Portfolio

Vertex Pharmaceuticals Announces UK MHRA Approval of ALYFTREK®?

Full year 2024 earnings released: US$2.08 loss per share (vs US$14.05 profit in FY 2023)

Vertex Pharmaceuticals Incorporated Executive Changes

Vertex Pharmaceuticals Incorporated Announces FDA Approval of Journavx (Suzetrigine), A First-In-Class Treatment for Adults with Moderate-To-Severe Acute Pain

Vertex Pharmaceuticals Incorporated to Report Q4, 2024 Results on Feb 10, 2025

Vertex Pharmaceuticals Incorporated Announces U.S. FDA Approval for Trialta® (elexacaftor/ivacaftor andivacaftor) to Include Additional Non-F508del TrialKAFTA-Responsive Variants

Vertex Pharmaceuticals Incorporated Announces Results from Phase 2 Study of Suzetrigine for Treatment of Painful Lumbosacral Radiculopathy

Vertex Pharmaceuticals Incorporated Presents Positive Long-Term Data on Casgevy at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update

Third quarter 2024 earnings released: EPS: US$4.05 (vs US$4.01 in 3Q 2023)

Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024

Vertex Pharmaceuticals Incorporated to Report Q3, 2024 Results on Nov 04, 2024

Second quarter 2024 earnings released: US$13.92 loss per share (vs US$3.55 profit in 2Q 2023)

Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024

Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-To-Severe Acute Pain

Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Marketing Authorization for Trikafa® for People with Cystic Fibrosis Aged 2 Years and Older with Certain Rare Mutations

Vertex Pharmaceuticals Incorporated to Report Q2, 2024 Results on Aug 01, 2024

Vertex Pharmaceuticals, Inc. Announces Positive Results from Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) completed the acquisition of Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders.

Vertex Pharmaceuticals Incorporated Appoints Jennifer Schneider as Independent Director

Vertex Pharmaceuticals Incorporated Re-Iterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$4.26 (vs US$2.72 in 1Q 2023)

Vertex Pharmaceuticals Announces European Commission Approval for KALYDECO to Treat Infants with Cystic Fibrosis Ages 1 Month and Older

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion.

Vertex Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 06, 2024

Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 15, 2024

Vertex Pharmaceuticals Incorporated Announces New Drug Submission for Exagamglogene Autotemcel (Exa-Cel) Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Receives CHMP Positive Opinion for KALYDECO for the Treatment of Infants with Cystic Fibrosis Ages 1 Month and Older

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Positive Results from Pivotal Trials of Vanza Triple Combination Treatment for Cystic Fibrosis

Vertex Pharmaceuticals Incorporated Provides Product Revenue Guidance for the Full Year 2024

Full year 2023 earnings released: EPS: US$14.05 (vs US$12.97 in FY 2022)

Vertex Announces Positive Results from the VX-548 Phase 3 Program for the Treatment of Moderate-To-Severe Acute Pain

Vertex Pharmaceuticals Incorporated to Report Q4, 2023 Results on Feb 05, 2024

Vertex Pharmaceuticals Incorporated Announces US FDA Approval of CASGEVY™ (Exagamglogene Autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Kingdom of Saudi

Vertex Pharmaceuticals Incorporated Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States

Vertex Pharmaceuticals Incorporated Appoints Nancy Thornberry to Its Board of Directors as an Independent Director

Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older

Vertex Pharmaceuticals Incorporated Announces European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5

Vertex Pharmaceuticals Incorporated Announces United Kingdom Medicines and Healthcare Products Regulatory Agency Granted Conditional Marketing Authorization for CASGEVY

Third quarter 2023 earnings released: EPS: US$4.01 (vs US$3.63 in 3Q 2022)

Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Market Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 To 5 Years With at Least One F508del Mutation

Vertex Pharmaceuticals Incorporated to Report Q3, 2023 Results on Nov 06, 2023

Vertex Pharmaceuticals Incorporated Appoints Michel Lagarde to Its Board of Directors

Vertex Pharmaceuticals Incorporated Receives Chmp Positive Opinion for Kaftrio® (Ivacaftor/Tezacaftor/Elexacaftor) in Combination with Ivacaftor for Children with Cystic Fibrosis Ages 2 Through 5

Vertex Pharmaceuticals Incorporated Appoints E. Morrey Atkinson, Ph.D., as Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations

Vertex Pharmaceuticals Incorporated Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine

Second quarter 2023 earnings released: EPS: US$3.55 (vs US$3.17 in 2Q 2022)

Vertex Pharmaceuticals Incorporated Announces European Commission Approval for ORKAMBI® (Lumacaftor/Ivacaftor) for the Treatment of Children with Cystic Fibrosis Ages 1 to <2 Years Old

Insufficient new directors

Vertex Pharmaceuticals Incorporated Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions

Vertex Pharmaceuticals Incorporated and Crispr Therapeutics Announces Positive Results from Pivotal Trials of Exa-Cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce FDA Accepts Biologics License Applications for Exagamglogene Autotemcel (Exa-Cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

First quarter 2023 earnings released: EPS: US$2.72 (vs US$2.99 in 1Q 2022)

Full year 2022 earnings released: EPS: US$12.97 (vs US$9.09 in FY 2021)

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) announces an Equity Buyback for $3,000 million worth of its shares.

Vertex Pharmaceuticals Incorporated to Report Q4, 2022 Results on Feb 07, 2023

Third quarter 2022 earnings released: EPS: US$3.63 (vs US$3.30 in 3Q 2021)

Second quarter 2022 earnings released: EPS: US$3.17 (vs US$0.26 in 2Q 2021)

First quarter 2022 earnings released: EPS: US$2.99 (vs US$2.52 in 1Q 2021)

Analys av ersättningar till VD